-
Product Insights
New![]()
Net Present Value Model: Vaxxinity Inc’s UB-311
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Vaxxinity Inc's UB-311 Drug Details: UB-311 is under development for the treatment of Alzheimer's disease (AD). The vaccine candidate is an anti-amyloid endobody...
-
Product Insights
New![]()
Net Present Value Model: Vaxxinity Inc’s UB-312
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Vaxxinity Inc's UB-312 Drug Details: UB-312 is under development for the treatment of Parkinson's disease and multiple system atrophy (MSA) and for dementia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UB-313 in Migraine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UB-313 in Migraine Drug Details: Vaccine candidate is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UB-312 in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.UB-312 in Parkinson's DiseaseDrug Details:UB-312 is under development for the treatment of Parkinson's disease and multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UB-311 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.UB-311 in Alzheimer's DiseaseDrug Details:UB-311 is under development for the treatment of Alzheimer's disease (AD). The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – UB-312 in Lewy Body Dementia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.UB-312 in Lewy Body DementiaDrug Details:UB-312 is under development for the treatment of Parkinson's disease and...
-
Company Insights
![]()
UBS Group – Digital Transformation Strategies
UBS Digital Transformation Strategies Report Overview UBS uses emerging technologies as a part of its digital transformation strategies. The annual ICT spending of UBS was estimated at $4 billion in 2022. A major share of this spending is earmarked for acquiring software, network and communications, and ICT services from vendors. UBS Group (UBS) is a provider of wealth management, banking, asset management, and investment banking solutions. The UBS Personal & Corporate Banking product portfolio consists of financing and investing as...
-
Company Insights
![]()
UBS Global Wealth Management – Competitor Profile
This report provides a comprehensive analysis of UBS’s wealth management operations. It offers insights into the company’s strategy and financial performance, including key data on assets under management. Customer targeting and service propositions are covered, as are product innovation and marketing activities. Headquartered in Switzerland, UBS is a global organization with a physical wealth management presence in over 50 countries. It operates through four business divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, and Investment Bank. UBS is...
-
Track & Monitor
New![]()
Banking and Payments Venture Capital Investments in Q2 2023
GlobalData's Banking & Payments (B&P) VentureView report provides detailed coverage of the global venture capital investment activity in Banking & Payments industry in Q3 2023, covering key insights and trends.
-
Company Insights
New![]()
LGT Private Banking – Competitor Profile
This report provides comprehensive analysis of LGT Private Banking's operations. It offers insight into the company’s strategy and financial performance, including key data on assets under management. Customer targeting, service proposition, product innovation, and marketing activities are also covered. Headquartered in Vaduz, Liechtenstein, LGT Group is a private banking and asset management firm that is fully controlled by the Princely Family of Liechtenstein. The group operates from more than 25 locations across Europe, Asia-Pacific, and the Middle East.
-
Company Insights
![]()
Pictet Group – Competitor Profile
GlobalData’s 'Pictet Group - Competitor Profile' provides a comprehensive analysis of Pictet’s private banking and wealth management operations. It offers insights into the company’s strategy and financial performance, including key data on assets under management (AUM). Customer targeting and service propositions are covered, as are product innovation and marketing activities. Headquartered in Geneva, Switzerland, Pictet Group is a corporate partnership offering wealth management and investment services in Europe, Asia, the Americas, and the Middle East. The group has 30 offices...
-
Sector Analysis
New![]()
Switzerland Wealth Management – Market Sizing and Opportunities to 2027
Switzerland Wealth Management Report Overview Switzerland’s affluent population (including HNW and mass affluent individuals) has shown steady growth in recent years. Collectively, HNW and mass affluent individuals accounted for more than 95% of the total population in 2022. It is among the highest in the world.​ The Switzerland Wealth Management market research report will help to keep up to date with the Swiss wealth management industry, looking at investors’ asset allocation by affluence bandings as well as a detailed picture of where...
-
Company Insights
![]()
RBC Wealth Management – Competitor Profile
Headquartered in Toronto, Canada, Royal Bank of Canada (RBC) Wealth Management is one of the five main business segments of RBC, the largest commercial bank in the country. This segment has five divisions, including the company’s Global Asset Management unit. RBC Wealth Management has 1,950 investment advisors in Canada and 2,100 financial advisors in the US. It also maintains offices in seven other countries. This report provides comprehensive analysis of RBC's wealth management operations. It offers insight into the company’s...
-
Product Insights
![]()
Ube Ind – Ube Polyimide Film Manufacturing Factory – Yamaguchi
Equip yourself with the essential tools needed to make informed and profitable decisions with our Ube Ind - Ube Polyimide Film Manufacturing Factory - Yamaguchi report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
New![]()
Net Present Value Model: Tarsus Pharmaceuticals Inc’s Lotilaner
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biomea Fusion Inc’s BMF-219
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
![]()
TS Alfresa Corp – TS Alfresa Ube Branch Ube Distribution Center – Yamaguchi
Equip yourself with the essential tools needed to make informed and profitable decisions with our TS Alfresa Corp - TS Alfresa Ube Branch Ube Distribution Center - Yamaguchi report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Thematic Analysis
New![]()
Batteries – Thematic Intelligence
Batteries Thematic Report Overview Batteries are critical facilitators of many other technologies. They are integral to modern mobile internet, electric cars, and the initial adoption of intermittent renewable power storage and generation. Batteries are clean technology that will likely be critical to the energy transition in the future. They are poised to become one of the world’s most significant industries over the next 10 years given stored energy's accelerating and expanding role in tackling climate change. The Batteries thematic intelligence...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Semzuvolimab in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Semzuvolimab in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details:UB-421 is under development for the prevention...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.